Melisa Wong on Age Disparities in Treatment for NSCLC Recurrence

Video

Melisa Wong, MD, Oncology Chief Fellow, Hematology/Oncology at the University of California San Francisco, discusses differences among age groups in the treatment of non–small cell lung cancer (NSCLC).

Melisa Wong, MD, Oncology Chief Fellow, Hematology/Oncology at the University of California San Francisco, discusses differences among age groups in the treatment of non—small cell lung cancer (NSCLC).

In a study involving more than 9000 patients with NSCLC, Wong found that the older a patient was, the less likely he or she was to receive active treatment for recurrence. There was about a 25% drop in the likelihood of getting active treatment for every decade a patient aged, according to Wong.

The study did not explore why this disparity exists, but Wong theorized that it may be due to either bias, since patients over 70 may seem unfit to receive treatments such as chemotherapy, or the choice of some older patients to more comfortably live out the remainder of their life.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Recent Videos
4 experts in this video
4 experts in this video
Photo of a woman wearing a blazer and a colorful scarf in front of a blue background
Photo of a woman with red hair and glasses wearing a black blouse and cross necklace in front of a dark blue background